ibandronic acid


Also found in: Dictionary, Wikipedia.

ibandronic acid

Pharmacologic class: Bisphosphonate

Therapeutic class: Calcium regulator

Pregnancy risk category C

Action

Inhibits osteoclast activity and reduces bone resorption and turnover; in postmenopausal women, reduces elevated bone turnover rate, leading to (on average) net gain in bone mass

Availability

Solution for injection: 3 mg/3 ml in single-use prefilled glass syringes

Tablets (film-coated): 2.5 mg, 150 mg

Indications and dosages

Osteoporosis treatment and prevention in postmenopausal women

Adults: 2.5-mg tablet P.O. daily, or 150-mg tablet P.O. once monthly on same date each month

Osteoporosis treatment in postmenopausal women

Adults: 3 mg I.V. injection every 3 months

Contraindications

• Hypersensitivity to drug or its components
• Uncorrected hypocalcemia
• Inability to stand or sit upright for at least 60 minutes (after oral administration)
• Abnormalities of esophagus, such as stricture or achalasia, that delay esophageal emptying (tablets)

Precautions

Use cautiously in:
• severe renal impairment (not recommended)
• active upper GI disease (such as Barrett's esophagus, dysphagia, other esophageal diseases, gastritis, duodenitis, or ulcers)
• patients who develop jaw osteonecrosis during therapy
• concurrent use of aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), or other bisphosphonates
• pregnant or breastfeeding patients
• children younger than age 18 (safety and efficacy not established).

Administration

• With patient standing or sitting upright, give oral dose with 6 to 8 oz water at least 60 minutes before first food or drink (other than water) of day or before administering other oral drugs or supplements (including calcium, antacids, and vitamins).
• Give with plain water only; some mineral waters may have higher calcium concentration and shouldn't be used.
• Don't let patient chew or suck tablet because this may cause oropharyngeal ulcers.
• Keep patient upright for at least 60 minutes after oral dose to avoid serious esophageal irritation.
• Give parenteral formulation only by I.V. injection over 15 to 30 seconds.
• Don't mix parenteral formulation with calcium-containing solutions or other I.V. drugs.
• If patient misses I.V. dose, give it as soon as possible; thereafter, give dose every 3 months from date of last injection. Don't administer more often than every 3 months.

Adverse reactions

CNS: insomnia, asthenia, headache, fatigue, dizziness, vertigo, nerve root lesion

CV: hypertension

EENT: pharyngitis

GI: constipation, diarrhea, vomiting, abdominal pain, dysphagia, esophagitis, esophageal irritation (tablets), gastric ulcer, dyspepsia, gastritis, esophageal ulcer

GU: urinary tract infection

Metabolic: hypercholesterolemia, hypocalcemia

Musculoskeletal: osteonecrosis (mainly in jaw), localized osteoarthritis and muscle cramp, joint disorder, joint pain, muscle pain, back pain, extremity pain, arthritis

Respiratory: upper respiratory tract infection, bronchitis, pneumonia

Skin: rash

Other: tooth disorder, influenza, infection, injection site reaction, allergic reaction

Interactions

Drug-drug.Aspirin, NSAIDs: additive GI irritation

Drugs containing calcium and other multivalent cations (such as aluminum, iron, magnesium), including antacids, supplements, and vitamins: interference with ibandronate absorption

Drug-diagnostic tests.Alkaline phosphatase, calcium: decreased

Bone-imaging agents: interference with test results

Drug-food.Milk, mineral water, other foods and beverages: interference with ibandronate absorption, reducing drug's bioavailability and effect on bone mineral density (when patient consumes food or beverage less than 60 minutes after ibandronate dose)

Patient monitoring

• Monitor creatinine clearance in patients with mild or moderate renal impairment.

Monitor for signs and symptoms of GI irritation (including ulcers) after oral administration; discontinue drug if new or worsening symptoms occur.
• Evaluate serum calcium and phosphate levels.
• Monitor for hypocalcemia and other disturbances of bone and mineral metabolism; administer effective treatment before therapy starts.
• Monitor patient for adequate intake of supplemental calcium and vitamin D during therapy, as appropriate.

Patient teaching

• Advise patient to read patient information leaflet carefully before starting drug.
• Instruct patient to take drug first thing in morning on empty stomach with 6 to 8 oz of plain water only.

Caution patient not to chew or suck tablet because this may cause throat ulcers.
• Instruct patient not to eat, drink, or take other oral medications for 60 minutes after taking tablet.

Caution patient not to lie down for at least 60 minutes after taking drug.
• Advise patient to take once-monthly tablet (150 mg) on same date each month.
• If patient misses once-monthly dose and next scheduled dose is more than 7 days away, instruct her to take one 150-mg tablet in morning after the day she remembers it and then resume taking one 150-mg tablet every month in morning of chosen day, per original schedule. However, if next scheduled dose is only 1 to 7 days away, tell her to wait until next scheduled dose.

Instruct patient to stop drug and immediately report heartburn, serious vomiting, severe chest or abdominal pain, difficulty swallowing, severe bone, joint, or muscle pain.
• If drug is prescribed for injection, tell patient she will receive it every 3 months.
• Advise patient to take supplemental calcium and vitamin D as prescribed, if dietary intake is inadequate.
• Teach patient to take only those pain relievers recommended by prescriber. Point out that some over-the-counter pain preparations (such as aspirin and NSAIDs) may worsen adverse effects.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and foods mentioned above.

ibandronic acid

A biphosphonate drug that act directly on bone to inhibit osteoclastic activity. The drug is used to treat high levels of blood calcium caused by malignant tumours whether or not bone secondaries are present. It is also used to prevent pathological fractures. A brand name is Bondronate.
References in periodicals archive ?
Mylan Inc (Nasdaq: MYL), a pharmaceutical company, on Fridayannounced that its United Kingdom and Italy-based subsidiaries have introduced Ibandronic Acid Film Coated Tablets POM, 150 mg.
The open-label study of 127 patients with breast cancer and bone metastases showed no clinically relevant changes in serum creatinine (SCr) levels in either group, indicating that patients were unlikely to suffer any renal impairment as a consequence of ibandronic acid therapy.
Limited tenders are invited for supply of various items Tab Daflon 500mg, Tab Warfarin 5 mg, Tab Ginkgo Biloba 40mg, Tab Drotaverine 80mg+ Mefnamic Acid 250mg, Tab Ibandronic Acid 150mg, Tab Valacyclovir 500mg, Cap Itraconazole 100mg, Cap Rifampicin 450 mg+ Isoniazid 300 mg of medicines to mh jalandhar
Dostawa heparyn drobnoczasteczkowych Nadroparyny i Dalteparyny, produktu leczniczego Ibandronic Acid, antybiotykw, produktw leczniczych: Rituximab, Etanercept, Adalimumab, Tocilizumab, Infliximab, Rivaroxaban, lekw rznych, pproduktw do zywienia pozajelitowego i dojelitowego, plynw infuzyjnych, Mannitolu oraz formaldehydu 10 %.
3 mq, Tab Nebivolol 5 ma, Tab Dabiaartan 110 ma, Tab Gramin 500 rnq, Tab Tamoxifen 20 ma, Ini Hvdroxv oroaesterone 250 ma, ln Penidure ( Benzathiline Pencillin), Svo Bromhexine bott of 100 ml, Inh Aerocort 400 ma, Ini Ibandronic Acid, Respules Levolin etc.
Supply of low molecular weight heparin - nadroparin and dalteparin, a medicinal product Ibandronic Acid, antibiotics, medicinal products: Rituximab, Etanercept, Adalimumab, Tocilizumab, Infliximab, Rivaroxaban, a variety of drugs, pproduktw for parenteral and enteral feeding, infusion solutions, Mannitol and 10% formaldehyde.
Tenders are invited for Tablet Ibandronic Acid 150 Mg.
Drug delivery: Strontium ranelate SKL code: 0028269 Protelos 2 G 0028270 Protelos 2G ibandronic SKL code: 0025422 Bonviva 150 mg 0,026,099 Bonviva 3 mg / 3 ml 0,202,820 Flastin 150 mg film-coated tablets 0,200,688 Gerousia 150 mg 0,161,377 Ibandronate Apotex 150mg 0,140,635 Ibandronate tablets 0,158,605 150 mg Ibandronic Acid Actavis 150 mg Ibandronic Acid Sandoz 0,187,866 150 0,198,304 mg Ibandronic Acid Stada 150 mg film-coated tablets 0,167,783 Ibandronic Acid Teva 150 mg 0,177,176 Ibandronic Acid Teva 3 mg solution for injection in pre-filled.